Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Non Operating Income (2017 - 2025)

Aclaris Therapeutics has reported Non Operating Income over the past 9 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Non Operating Income at $2.9 million for Q4 2025, down 5.89% from a year ago — trailing twelve months through Dec 2025 was $11.5 million (up 16.08% YoY), and the annual figure for FY2025 was $11.5 million, up 16.06%.
  • Non Operating Income for Q4 2025 was $2.9 million at Aclaris Therapeutics, up from $2.5 million in the prior quarter.
  • Over the last five years, Non Operating Income for ACRS hit a ceiling of $3.1 million in Q4 2024 and a floor of -$851000.0 in Q3 2021.
  • Median Non Operating Income over the past 5 years was $1.9 million (2024), compared with a mean of $1.6 million.
  • Biggest five-year swings in Non Operating Income: crashed 338.66% in 2021 and later soared 1522.47% in 2022.
  • Aclaris Therapeutics' Non Operating Income stood at $89000.0 in 2021, then skyrocketed by 1522.47% to $1.4 million in 2022, then skyrocketed by 51.59% to $2.2 million in 2023, then skyrocketed by 42.67% to $3.1 million in 2024, then dropped by 5.89% to $2.9 million in 2025.
  • The last three reported values for Non Operating Income were $2.9 million (Q4 2025), $2.5 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.